Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 9,563 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 9,563 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $1,323,614.83. Following the transaction, the chief executive officer now directly owns 212,541 shares of the company’s stock, valued at approximately $29,417,799.81. The trade was a 4.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The shares were sold at an average price of $146.03, for a total value of $978,693.06.
• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The stock was sold at an average price of $143.40, for a total transaction of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41.

Natera Stock Performance

Shares of NTRA stock opened at $140.65 on Wednesday. The firm has a market cap of $19.01 billion, a price-to-earnings ratio of -79.91 and a beta of 1.80. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company’s 50 day moving average is $158.72 and its 200 day moving average is $151.35.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the topic of several recent research reports. Royal Bank of Canada assumed coverage on Natera in a report on Thursday, March 13th. They set an “outperform” rating and a $251.00 price target on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. Morgan Stanley upped their price target on shares of Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. BTIG Research reissued a “buy” rating on shares of Natera in a research report on Friday, February 28th. Finally, Robert W. Baird boosted their target price on Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Institutional Trading of Natera

Several hedge funds have recently modified their holdings of NTRA. Vanguard Group Inc. grew its position in shares of Natera by 7.7% in the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company’s stock worth $1,949,697,000 after buying an additional 879,463 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company’s stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Natera by 43.7% during the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company’s stock worth $1,060,836,000 after purchasing an additional 2,036,396 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company’s stock valued at $512,898,000 after purchasing an additional 439,778 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Natera by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company’s stock valued at $355,809,000 after purchasing an additional 142,201 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.